Results 41 to 50 of about 19,810 (202)

Systematic review of clinical trials and cohort studies evaluating HIV post‐exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background We conducted a systematic review of clinical trials and cohort studies on HIV post‐exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines. Methods We searched Medline and Embase (July 2017–June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and/
Stanley O. Onyegbule, Maryam Habib, Rija Khalid, Jessie Tu, Deborah Yoong, Jaris Swidrovich, Wale Ajiboye, Patrick O'Byrne, Ameeta E. Singh, Jean‐Guy Baril, Tatiana Sotindjo, Mark W. Hull, Darrell H. S. Tan   +12 more
wiley   +1 more source

Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient [PDF]

, 2017
Fanconi syndrome is a rare adverse effect of tenofovir disoproxil fumarate (TDF). Tenofovir alafenamide fumarate (TAF) is a novel prodrug with less nephrotoxicity.
Maile Young Karris, Karris, Maile Young
core   +1 more source

Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring

British Journal of Clinical Pharmacology, EarlyView.
Lenacapavir (LEN), a first‐in‐class capsid inhibitor, has unique pharmacokinetics that enable twice‐yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug–drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant ...
Aaron S. Devanathan, Thomas Glowa, Emily M. Thompson, Amanda J. Saylor, Thomas D. Nolin, Sharon A. Riddler, Ken S. Ho   +6 more
wiley   +1 more source

Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients

, 2020
International audienceTenofovir disoproxil fumarate is a prodrug of tenofovir diphosphate that exposes patients to renal toxicity over the long term. Tenofovir alafenamide, a new prodrug, now makes it possible to reduce toxicity, but at the cost of an ...
Muret, Patrice, Kowalczyk, Jakub, Bozon, Fabienne, Chirouze, Catherine, Davani, Siamak, Lagoutte-Renosi, Jennifer, Beckwirth, Geneviève, Brunel, Anne-Sophie, Drobacheff-Thiebaut, Marie-Christine, Michel, Catherine, Flammang, Mylène, Hustache-Mathieu, Laurent, Foltzer, Adeline   +12 more
core   +1 more source

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV

Journal of Renal and Hepatic Disorders, 2018
Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections.
Nicole Marie Lioufas, Alan Street, Paul Champion de Crespigny, Stephen G Holt   +3 more
doaj   +1 more source

Tenofovir diphosphate intracellular concentration following tenofovir alafenamide administration in bictegravir‐containing vs. dolutegravir‐containing antiretroviral regimens

British Journal of Clinical Pharmacology, EarlyView.
This study investigates intracellular (IC) exposure of tenofovir alafenamide (TAF) and its clinical determinants in experienced people living with HIV. We conducted a monocentric retrospective analysis of 86 adults treated with either bictegravir (BIC)‐ or dolutegravir (DTG)‐containing regimen. Plasma and IC trough concentrations (Ctrough) of tenofovir
Micol Ferrara, Viviana Maccario, Silvia Fantino, Erica Clemente, Federica Barrera, Alice Palermiti, Sara Soloperto, Amedeo De Nicolo, Antonio D'Avolio, Giovanni Di Perri, Stefano Bonora   +10 more
wiley   +1 more source

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: different effects in different patients populations : results from a large observational study [PDF]

, 2019
Tenofovir alafenamide (TAF) has similar efficacy compared to tenofovir disoproxil fumarate (TDF), but a less favorable effect on lipids. Aim of this study was to evaluate the impact on lipids of switching from rilpivirine (RPV)/ emtricitabine (FTC)/TDF ...
N. Riccardi, L. Taramasso, M. Giacomini, F. Maggiolo, F. Briano, A. Gori, E. Di Filippo, A. Di Biagio, L. Comi, S. Mora   +9 more
core   +3 more sources

Evaluating Vaginal Microbiome Effects on Antiretroviral Exposure in the Female Genital Tract Using Pharmacometric and Machine Learning Approaches

Clinical Pharmacology &Therapeutics, EarlyView.
Antiretroviral pre‐exposure prophylaxis (PrEP) is less effective in women than expected, partly because drug exposure within the female genital tract is variable and may be influenced by the vaginal microbiome. We developed an integrated pharmacometrics and machine learning framework to evaluate associations between vaginal microbiome composition and ...
Diqin Yan, Lindsey B. Collins, Christopher Staley, Flavia Kiweewa Matovu, Pamala Jacobson, Melanie Nicol, Shen Cheng   +6 more
wiley   +1 more source

Comparative analysis of tenofovir alafenamide and entecavir on renal function and serum lipids in liver transplant recipients: a controlled retrospective cohort study

BMC Gastroenterology
Background Antiviral treatments can impact serum lipids as well as kidney function. We conducted a retrospective observational study with a 48-month follow-up period, involving liver transplant recipients receiving either entecavir or tenofovir ...
Hüseyin Döngelli, Nilay Danış, Tarkan Ünek, Tufan Egeli, Cihan Ağalar, Mücahit Özbilgin, Hülya Ellidokuz, Mesut Akarsu   +7 more
doaj   +1 more source

Machine Learning Model for Predicting Hepatocellular Carcinoma Development in Patients With Hepatitis B Virus‐Related Cirrhosis Receiving Antiviral Therapy

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Few prediction models have been specifically designed to evaluate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B and cirrhosis. This study aimed to develop a machine learning‐based prediction model to assess the risk of developing HCC in patients with hepatitis B virus (HBV)‐related cirrhosis undergoing nucleos(
Pao‐Yuan Huang, Heng‐Syu Lin, Cheng‐Yuan Peng, Ruei‐Hau Hsu, Chien‐Hung Chen   +4 more
wiley   +1 more source